TrialOncoimmunology2026

Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma.

Lorenzo Falchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.